MedTech Innovation Briefing is the NICE's advice program for innovative technologies. It provides an overview of clinical effectiveness, safety and cost. It does not offer a formal guidance, and it, therefore, does not provide any recommendations.
Two new Medtech Innovation Briefings, including EpiFix for chronic wounds (an amniotic membrane allograft comprised of dehydrated human amniotic membrane for treating chronic wounds such as diabetic foot ulcers and venous leg ulcers) and minimally invasive percutaneous nephrolitholapaxy medium (MIP-M) for removing kidney stones (minimally invasive percutaneous nephrolitholapaxy medium (MIP‑M) used to remove kidney stones) have been published the second half of January.
In the second half of January NICE published new Clinical Guideline Oesophago-gastric cancer: assessment and management in adults. This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support. It provides specific recommendadtions for surgical treatment using endoscopic techniques, including:
- endoscopic mucosal resection for staging for people with suspected T1 oesophageal cancer;
- endoscopic eradication of remaining Barrett's mucosa for people with T1aN0 oesophageal cancer;
- an open or minimally invasive (including hybrid) oesophagectomy for surgical treatment of oesophageal cancer.
See full details here.
Subscribe to our newsletter delivered every second week not to miss important reimbursement information.